Ligand Pharmaceuticals (LGND) Enterprise Value (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Enterprise Value of -$779.4 million for Q1 2026, down 6.26% sequentially from -$733.5 million in Q4 2025, and down 273.1% YoY from $450.3 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Enterprise Value (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$779.4 million in Q1 2026.
- Quarterly Enterprise Value fell 273.1% year-over-year to -$779.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$779.4 million (down 273.1% YoY) and the FY2025 annual result came in at -$733.5 million, down 186.35% from the prior year.
- Enterprise Value fell to -$779.4 million in Q1 2026 per LGND's latest filing, from -$733.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$38.3 million in Q2 2024 and troughed at -$779.4 million in Q1 2026.
- A 5-year average of -$285.8 million and a median of -$211.9 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 82.52% in 2024, then sank 788.97% in 2025.
- Over 5 years, Enterprise Value stood at -$211.9 million in 2022, then rose by 19.62% to -$170.3 million in 2023, then slumped by 50.41% to -$256.2 million in 2024, then sank by 186.35% to -$733.5 million in 2025, then slipped by 6.26% to -$779.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$779.4 million, -$733.5 million, and -$664.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | -1.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.36 Bn |
| Mar 31, 2026 | -779.41 Mn |
| Dec 31, 2025 | -733.52 Mn |
| Sep 30, 2025 | -664.52 Mn |
| Jun 30, 2025 | -245.02 Mn |
| Mar 31, 2025 | -208.90 Mn |
| Dec 31, 2024 | -256.17 Mn |
| Sep 30, 2024 | -74.75 Mn |
| Jun 30, 2024 | -38.28 Mn |
| Mar 31, 2024 | -310.59 Mn |
| Dec 31, 2023 | -170.31 Mn |
| Sep 30, 2023 | -190.50 Mn |
| Jun 30, 2023 | -219.04 Mn |
| Mar 31, 2023 | -282.67 Mn |
| Dec 31, 2022 | -211.87 Mn |
| Sep 30, 2022 | -121.41 Mn |
| Jun 30, 2022 | -147.94 Mn |
| Mar 31, 2022 | -204.00 Mn |
| Dec 31, 2021 | -341.11 Mn |
| Sep 30, 2021 | -323.21 Mn |